Corbus Pharmaceuticals Holdings CRBP
NASDAQ CRBP
$9.84 -0.15 (-1.50%)
At close: Aug 20, 2026 · 4:00 PM EDT

Corbus Pharmaceuticals Holdings (CRBP) Restructuring Costs (2022)

Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Restructuring Costs of $5.0 million for Q2 2022.

Corbus Pharmaceuticals Holdings (CRBP) Restructuring Costs (2022) Analysis & Trends

Corbus Pharmaceuticals Holdings' Restructuring Costs history runs 1 years deep, the most recent figure standing at $5.0 million for Q2 2022.

  • In Q2 2022, Restructuring Costs changed N/A year-over-year to $5.0 million; the TTM figure through Jun 2023 stood at $5.0 million (changed N/A YoY), while the FY2022 annual figure was $5.0 million, changed N/A from the prior year.
  • Restructuring Costs for Q2 2022 stood at $5.0 million.
  • The five-year high for Restructuring Costs was $5.0 million in Q2 2022, with the low at $5.0 million in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn -
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn
10 Corbus Pharmaceuticals Holdings 121.72 Mn -41.55 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2022 5.00 Mn